Perfuse Therapeutics is conducting trials for the treatment for glaucoma and diabetic retinopathy, aiming to restore vision ...

With more options available than ever to treat patients with glaucoma, it has become clearer that treatment needs to occur as ...

Glaucoma is the second leading cause of blindness in the U.S.A primary screening tool for glaucoma is measurement of IOP. The ...

Glaukos (NYSE:GKOS) announced that it received EU MDR certification for its iStent Infinite, along with several other ...

In the time before widespread vaccination, young children often became disabled or lost their lives to whooping cough, ...

Before the vaccines, such illnesses were the main reason why nearly one in five children in 1900 never made it to their fifth ...

In the time before widespread vaccination, death often came early. Devastating infectious diseases ran rampant in America, ...

Long-term exposure to air pollution is associated with a significantly increased risk of primary open-angle glaucoma.

Glaukos has claimed a series of regulatory clearances in Europe for its micro-scale surgical implants to treat patients with ...

Nicox completed the Denali Phase 3 trial for NCX 470, targeting open-angle glaucoma and ocular hypertension. NCX 470 combines ...

Biological age acceleration is associated with an increased risk of glaucoma and elevated intraocular pressure.